Efgartigimod Alfa Dosage

Medically reviewed by Drugs.com. Last updated on Apr 2, 2024.

Usual Adult Dose for Myasthenia Gravis

10 mg/kg IV once weekly for 4 weeks

• Weight greater than 120 kg: 1200 mg IV once weekly for 4 weeks

Comments:

• Subsequent treatment cycles should be based on clinical evaluation.
• The safety of initiating a cycle sooner than 50 days from the start of the prior cycle has not been established.
• Evaluate the need for age-appropriate immunizations prior to therapy initiation.

Use: For the treatment of generalized myasthenia gravis in patients who are anti-acetylcholine receptor antibody positive.

Renal Dose Adjustments

Mild renal dysfunction (estimated GFR [eGFR] 60 to 89 mL/min/1.73 m2): No adjustment recommended.
Moderate to severe renal dysfunction (eGFR less than 6059 mL/min/1.73 m2): Data not available

Liver Dose Adjustments

No adjustment recommended

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer as an IV infusion over 1 hour; use a 0.2 micron in-line filter and flush line after administration.
• Administration should be performed by a healthcare professional.
• If a hypersensitivity reaction occurs during administration, discontinue infusion and institute appropriate supportive measures.

MISSED DOSE: If a scheduled infusion is missed, it may be administered up to 3 days after scheduled; original dosing schedule should be resumed until treatment cycle is complete.

Storage requirements:

• Prior to use: Store vials in refrigerator (36F to 46F [2C to 8C]) in the original carton to protect from light; do not freeze; do not shake.
• Once diluted, complete infusion within 4 hours.
• If immediate use is not possible, may store diluted solution in refrigerator for up to 8 hours; do not freeze, protect from light.
• Once diluted solution has been refrigerated, allow to reach room temperature via ambient air (do not heat in any other manner); complete infusion within 4 hours of removing from the refrigerator.

Reconstitution/preparation techniques:

• Prescribed dose should be gently withdrawn from vials and diluted with 0.9% sodium chloride to make a total volume of 125 mL for IV infusion.
• The diluted solution should be gently inverted without shaking to ensure thorough mixing.
• The diluted solution can be administered using polyethylene (PE), polyvinyl chloride (PVC), ethylene vinyl acetate (EVA), or ethylene/polypropylene copolymer bags (polyolefins bags), and with PE, PVC, EVA, or polyurethane/polypropylene infusion lines.

IV compatibility:

• Should not be mixed with other drugs

General:

• Subsequent treatment cycles should be based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established.

Monitoring:

• Monitor patients for hypersensitivity reactions during administration and for 1 hour after.
• Monitor for infections.

Patient advice:

• Patients should be instructed to contact their healthcare provider if they develop an infection or any signs or symptoms of a hypersensitivity reaction.
• Patients are advised to discuss vaccination status with their healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer